A. Menarini Diagnostics and Sinocare announce exclusive distribution agreement for new continuous glucose monitoring system
Wednesday, December 04, 2024
A. Menarini Diagnostics announces an exclusive distribution agreement with Sinocare to register, promote, distribute and commercialize a new Sinocare third-generation continuous glucose monitoring (CGM) system in reimbursable markets. This groundbreaking agreement gives A. Menarini Diagnostics exclusive rights to launch this healthcare technology in more than 20 countries in Europe.
The collaboration between A. Menarini Diagnostics and Sinocare represents a significant advance in diabetes care. Sinocare's CGM system technology enables accurate and continuous blood glucose monitoring.
"The partnership with A. Menarini Diagnostics is a significant milestone in our efforts to make our 3rd generation CGM systems widely accessible to people with diabetes ," said Dr. Jiangfeng Fei , Head of CGM Business Unit, Sinocare. " We are pleased to enter into a strategic partnership with A. Menarini Diagnostics, a leading company in the healthcare industry, to make this innovative diabetes technology available to a wider audience."
A. Menarini Diagnostics shares this enthusiasm for the collaboration and its potential impact on diabetes care. " Securing exclusive rights to distribute and commercialize the Sinocare 3rd Generation CGM System in various countries is in line with our commitment to providing innovative healthcare solutions ," commented Fabio Piazzalunga, General Manager and Global Head of A. Menarini Diagnostics. " We are confident that this long-term partnership will meet the growing demand for advanced diabetes care ."
By leveraging its extensive network, expertise and resources, A. Menarini Diagnostics aims to ensure that Sinocare 3rd Generation CGM systems reach those who can most benefit from their advanced capabilities. This partnership is expected to significantly expand the availability of Sinocare's 3rd Generation CGM systems.
About A. Menarini Diagnostics
A. Menarini Diagnostics is a leading healthcare company committed to providing innovative solutions for better health outcomes through advanced diagnostic tools and technologies. For more than 45 years, the company has been dedicated to helping healthcare professionals make safe and sustainable diagnoses, improving the quality of life of people around the world. A. Menarini Diagnostics is part of the Menarini Pharmaceutical Group, founded in 1886. Today, the company is present in 140 countries around the world, employs more than 17,000 people and has a turnover of €4.375 billion in 2023.
About Sinocare
Sinocare is the largest manufacturer of blood glucose meters in Asia. Founded in 2002, Sinocare Inc. was the first blood glucose meter company to go public in China . With a commercial presence in Asia, Europe and North America, Sinocare has expanded internationally through partnerships and acquisitions such as U.S. -based PTS Diagnostics Inc. and Nipro Diagnostic Inc. (now Trividia Health Inc.).
Our commitment to innovation in biosensing has made Sinocare the world's fourth largest blood glucose meter manufacturer and one of the world's leading POCT companies.
Source: prnewswire.com